A Study of IBI112 in Chinese Patients With Psoriasis Who Were Previously Treated With Biologics

Inclusion Criteria: 18 to 75 years old; Evaluated suitable for continuing biologic therapy for plaque psoriasis by the investigator; Received previous biologic therapy with at least 4 months. Exclusion Criteria: Previously or currently diagnosed with pustular psoriasis, erythrodermic psoriasis, or drug-induced psoriasis (e.g., psoriasis caused by beta blockers, calcium channel inhibitors, etc.); Or presenting with guttate psoriasis at screening or first dose administration; Previously treated with IBI112 or other IL-23 inhibitors; Treated with two biologics for psoriasis within 4 months prior to screening; Treated with topical therapy for psoriasis within 2 weeks prior to the first dose administration, or treated with systemic non-biological agents or phototherapy within 4 weeks prior to the first dose administration; Treated with Natalizumab, or B/T cell regulators (e.g., Rituximab, Abatacept, or Visilizumab) within 12 months prior to the first dose administration; Not willing to avoid constant sunshine and other ultraviolet light sources exposure during the study; Treated with an investigational biologic within 6 months prior to the first dose administration, or any investigational therapy within 30 days, or an investigational drug within 5 half-lives, or currently participating in a clinical study.